

? (b5)
wcl.

34. The method of claim 33, wherein said endonuclease recognition site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

35. The method of claim 34, wherein said endonuclease recognition site is a Class I I-endonuclease site.

36. The method of claim 35, wherein said endonuclease recognition site is selected from the group consisting of I-SceI, I-SceIV, I-CsmI, and I-PanI sites.

37. The method of claim 36, wherein said endonuclease recognition site is an I-SceI site. --

REMARKS

Entry and consideration of this amendment is respectfully requested.

Claims 1-26 have been canceled. New claims 27-37 find support throughout the specification, for example on pages 20-21 and Fig.6. Accordingly, no new matter is entered by amendment.

Applicants submit herewith a Sequence Listing and have amended the specification to conform with the requirements of 37 C.F.R. §§ 1.821-1.825.

Applicants request the use of the computer-readable form of the Sequence Listing in U.S. Application Serial No. 08/417,226, filed April 5, 1995, now U.S. Patent No. 5,962,327, issued October 5, 1999.